Cerebral organoids represent a revolutionary in vitro model system that recapitulates aspects of human brain architecture and function in three dimensions. These self-organizing structures provide unprecedented access to human neural development and disease mechanisms.
| Protocol |
Developer |
Key Features |
Applications |
| Lancaster |
Lancaster et al., 2013 |
Matrigel embedding, spinning flask |
Cortical development |
| Quadrato |
Quadrato et al., 2017 |
Improved maturation, single-cell |
Safety/toxicity screening |
| Bhaduri |
Bhaduri et al., 2020 |
AP-mediated patterning |
Regional specification |
| Yoon |
Yoon et al., 2019 |
Vascularized organoids |
Ischemia models |
- Days 0-5: Embryoid body formation from iPSCs/ESCs
- Days 5-10: Neural ectoderm induction via BMP/SMAD inhibition
- Days 10-20: Neuroepithelial cyst formation
- Days 20-60: Neural progenitor expansion, early neuronal differentiation
- Days 60-100+: Neuronal maturation, synapse formation, glial differentiation
- Cortical excitatory neurons: Glutamatergic pyramidal neurons
- Interneurons: GABAergic inhibitory neurons (when properly patterned)
- Subcortical neurons: Dopaminergic, serotonergic neurons (with regional patterning)
- Astrocytes: Emerge after day 60, perform metabolic support
- Oligodendrocytes: Myelinating glia (day 80+ with appropriate differentiation)
- Microglia: Rare in standard protocols; improved with myeloid co-culture
- Ventricular zones: Neural progenitor cycling zones
- Cortical plate: Layered neuronal architecture
- Subventricular zones: Secondary progenitor pools
- Synaptic networks: Functional excitatory and inhibitory connections
Cerebral organoids enable study of AD-relevant pathology in human tissue:
- Amyloid pathology: APP/PSEN1 organoids develop Aβ plaques and associated changes
- Tau pathology: Hyperphosphorylated tau in neuronal processes
- Neuroinflammation: Glial responses to amyloid deposition
- Synaptic dysfunction: Impaired LTP, reduced synaptic markers
| PD Model |
Approach |
Phenotype |
| LRRK2 G2019S |
Gene-edited iPSCs |
Altered neuronal morphology, stress sensitivity |
| SNCA triplication |
Patient-derived |
Increased α-synuclein aggregation |
| Idiopathic |
Patient-derived |
Mitochondrial dysfunction, metabolic changes |
| Mitochondrial |
Complex I inhibitors |
Dopaminergic neuron vulnerability |
- Huntington's disease: Mutant HTT aggregation, selective vulnerability
- Frontotemporal dementia: Tau pathology, neuronal loss
- Amyotrophic lateral sclerosis: TDP-43 pathology, motor neuron vulnerability
Cerebral organoids serve as preclinical testing platforms:
- Efficacy testing: Rescue of disease phenotypes (aggregation, neuronal survival)
- Toxicity assessment: Human-specific adverse effects
- Penetration studies: Blood-brain barrier drug penetration (with vascular organoids)
- Combination therapy: Multi-target drug interactions
- Development: Human-specific developmental processes
- Infection: Zika virus, SARS-CoV-2 neuropathogenesis
- Circuit dysfunction: Network activity abnormalities
- Cell-cell interactions: Glial-neuronal crosstalk
¶ Advantages and Limitations
- Human tissue: Human cells in a 3D context
- Complex architecture: Recapitulates brain region organization
- Long-term culture: Can be maintained for months
- Patient-specific: Disease modeling from individual patients
- Scalable: Multiple organoids from single iPSC line
- Variability: Organoid-to-organoid variation
- Lack of vasculature: Limits size and maturity (unless vascularized)
- Missing cell types: Microglia, oligodendrocytes often absent
- Incomplete maturation: Fetal-like rather than adult-like
- Ethics: Some concerns about consciousness-like activity
¶ Standardization
- Single-cell sequencing: Define cell type composition
- Functional assays: Calcium imaging, multi-electrode arrays
- Biochemistry: Protein/RNA analysis from pooled organoids
- Morphology: Histology, confocal imaging
- Use validated iPSC lines with regular karyotyping
- Include proper controls (isogenic, CRISPR-corrected)
- Characterize organoids at multiple timepoints
- Report differentiation efficiency and variability
- Account for batch effects in experimental design
- Lancaster et al., 2013 - Cerebral organoids model brain development
- Quadrato et al., 2016 - Single-cell genomics of human brain organoids
- Sloan et al., 2017 - 3D culture model of Alzheimer's disease
- Bhaduri et al., 2020 - Cellular diversity in human brain organoids
- Yoon et al., 2019 - Vascularized brain organoids